Tagged as: allegran

Amgen and Allergan Announce Positive Results from Clinical Study of Rituxan Biosimilar Candidate

On August 22, Amgen and Allergan announced positive top-line results from a clinical study (JASMINE) comparing the efficacy and safety of the biosimilar candidate ABP 798 (rituximab) to the reference drug Rituxan® in patients with CD20-positive B-cell non-Hodgkins lymphoma. As we reported in January, ABP 798 was previously found to…

Read More